Natco Pharma Ltd

Natco Pharma Ltd share price inched up 4.07% to Rs 952.25. The Company's net profit tanked by 47.62% to Rs 122.2 crore, while revenue from operations eased by 0.53% to Rs 735.2 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.19 lakh crore, gaining 4.69%. It has marginally improved by 0.66% over last one week and moving up by 11.20% in last one month while the market capitalization of Natco Pharma Ltd has improved by 3.83% and 20.49% in the same period respectively. Profit before tax (PBT) of Natco Pharma Ltd stood at Rs 185.6 crore in Q2 FY26, tumbling by 67.55% year-on-year, and surging by 28.80% quarter-on-quarter. EBITDA came in at Rs 127 crore, nosediving by 75.00% YoY and expanding by 155.62% sequentially. Total expenses slightly declined by 9.99% to Rs 595.8 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 157.8 crore, soaring by 53.50% YoY, while employee benefits expense was at Rs 179.3 crore, witnessing a strong rise of 13.12% YoY. For the TTM ended FY26, revenue from operations rose 10.77% to Rs 4429.5 crore, while net profit jumped 35.66% to Rs 1883.4 crore, compared to previous TTM. EBITDA jumped by 167070% to Rs 1841.5 crore, and PBT surged 36.92% to Rs 2291.4 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 1696.8 crore in FY26, as against Rs 1211.6 crore in FY25. Natco Pharma Ltd climbed 5.32% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 3.05% during the same period.

Natco Pharma Ltd. has declared an interim dividend of Rs 1.50 (75%) per equity share of Rs 2 each for the financial year 2026-27, with a record date set for August 20, 2026, and payment commencing on August 26, 2026.

Natco Pharma Limited will hold a board meeting on August 14, 2026, to consider and evaluate proposals for raising funds through the issuance of equity shares or other securities, potentially including a public issue, preferential issue, rights issue, private placement, or qualified institutions placement, subject to market conditions and regulatory approvals.

Natco Pharma Limited will hold a board meeting on August 14, 2026, to consider the unaudited financial results for the quarter ended June 30, 2026, and a potential interim dividend for the financial year ending 2026-27; trading window for company insiders will be closed from August 7, 2026, to August 16, 2026, and will reopen on August 17, 2026.

The approved abbreviated new drug application (ANDA) is therapeutically equivalent to the reference listed drug (RLD), Lynparza Tablets, marketed by AstraZeneca Pharmaceuticals, for the indications specified in the approved labelling. Under the partnership arrangement, NATCO Pharma will manufacture the Olaparib tablets, while Alembic Pharmaceuticals will distribute the product in the United States. Olaparib, marketed under the brand name Lynparza, is a targeted cancer therapy belonging to the class of PARP inhibitors. It is indicated for the treatment of certain types of ovarian, breast, pancreatic and prostate cancers by preventing cancer cells with specific genetic mutations, such as BRCA or HRR mutations, from repairing damaged DNA. The company said the Paragraph IV (Para IV) patent litigation related to the product is ongoing. According to industry sales data, Olaparib tablets recorded estimated U.S. sales of approximately USD 1.4 billion for the 12 months ended March 2026. NATCO Pharma, headquartered in Hyderabad, develops, manufactures and markets generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients (APIs) and crop protection products. The company reported a 34.11% year-on-year decline in consolidated net profit to Rs 267.9 crore in Q4 FY26, compared with Rs 406.6 crore in the corresponding quarter last year. Revenue from operations declined 39.46% YoY to Rs 739.1 crore during the quarter ended 31 March 2026. Powered by Capital Market - Live

Natco Pharma announced the successful completion of its acquisition of an additional 13.25% equity stake in Adcock Ingram Holdings Proprietary Limited (Adcock Ingram), a leading South African pharmaceutical and healthcare company. With the completion of this transaction, NATCO's shareholding in Adcock Ingram has increased from 35.75% to 49%. The acquisition was completed through NATCO Pharma South Africa Proprietary, NATCO's wholly owned subsidiary in South Africa. The transaction involved the acquisition of shares for an aggregate consideration of around ZAR 1.81 billion equivalent to around Rs 1,060 crore at the transaction exchange rate. NATCO first acquired 35.75% in Adcock Ingram through its participation in the Adcock Ingram's delisting process in 2025 following the announcement of a firm intention offer in July 2025, shareholder approval in October 2025 and completion of the transaction in November 2025.

The approved product is bioequivalent to Halaven Injection, the reference-listed drug (RLD) marketed by Eisai Inc. Eribulin Mesylate Injection is indicated for the treatment of adults with metastatic breast cancer who have previously undergone at least two chemotherapy regimens for metastatic disease. It is also used for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. According to IQVIA MAT data for April 2026, the reference drug Halaven recorded estimated annual sales of approximately $43.7 million in the United States. NATCO Pharma, headquartered in Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The company reported a 34.11% year-on-year decline in consolidated net profit to Rs 267.9 crore in Q4 FY26, compared with Rs 406.6 crore posted in the corresponding quarter last year. Revenue from operations fell 39.46% YoY to Rs 739.1 crore in the quarter ended 31 March 2026. The counter slipped 2.48% to Rs 915.80 on the BSE. Lupin is a global pharmaceutical company focused on branded and generic formulations, complex generics, biotechnology products and active pharmaceutical ingredients across multiple therapeutic segments. The company's consolidated profit after tax stood at Rs 1,468.70 crore in Q4 FY26, up 87.72% from Rs 782.40 crore in Q4 FY25 and higher by 24.42% from Rs 1,180.50 crore in Q3 FY26. Net sales rose 32.9% to Rs 7391.91 crore in Q4 FY26 from Rs 5562.2 crore in Q4 FY25. It increased 4.1% sequentially from Rs 7100.5 crore in Q3 FY26. The counter shed 0.20% to Rs 2,245.10 on the BSE. Powered by Capital Market - Live

Net profit of Natco Pharma declined 34.11% to Rs 267.90 crore in the quarter ended March 2026 as against Rs 406.60 crore during the previous quarter ended March 2025. Sales declined 39.47% to Rs 739.10 crore in the quarter ended March 2026 as against Rs 1221.00 crore during the previous quarter ended March 2025. For the full year,net profit declined 24.76% to Rs 1418.50 crore in the year ended March 2026 as against Rs 1885.40 crore during the previous year ended March 2025. Sales declined 7.93% to Rs 4078.30 crore in the year ended March 2026 as against Rs 4429.50 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales739.101221.00 -39 4078.304429.50 -8 OPM %17.2644.89 -35.2249.58 - PBDT194.50604.20 -68 1697.402526.60 -33 PBT144.10505.90 -72 1490.802291.40 -35 NP267.90406.60 -34 1418.501885.40 -25 Powered by Capital Market - Live

Revenue from operations fell 39.46% YoY to Rs 739.1 crore in the quarter ended 31 March 2026. Profit before tax (PBT) declined sharply by 71.51% to Rs 144.1 crore in Q4 FY26 from Rs 505.9 crore recorded in Q4 FY25. On the segmental front, revenue from the pharmaceuticals business stood at Rs 716.5 crore, down 40.58% year-on-year. Meanwhile, revenue from the agro chemicals segment increased 50.66% YoY to Rs 716.5 crore in Q4 FY26. For the full financial year FY26, Natco Pharma reported a 24.76% decline in consolidated net profit to Rs 1,418.5 crore. Revenue from operations decreased 7.92% year-on-year to Rs 4,078.3 crore in FY26. NATCO Pharma, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. Powered by Capital Market - Live

Delta Corp Ltd, ISGEC Heavy Engineering Ltd, Jyoti CNC Automation Ltd and Bharat Dynamics Ltd are among the other losers in the BSE's 'A' group today, 29 May 2026.Natco Pharma Ltd tumbled 10.70% to Rs 1049.8 at 14:46 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 1.18 lakh shares were traded on the counter so far as against the average daily volumes of 53556 shares in the past one month.Delta Corp Ltd lost 8.62% to Rs 74.01. The stock was the second biggest loser in 'A' group.On the BSE, 26.91 lakh shares were traded on the counter so far as against the average daily volumes of 2.64 lakh shares in the past one month.ISGEC Heavy Engineering Ltd crashed 8.55% to Rs 944.4. The stock was the third biggest loser in 'A' group.On the BSE, 10635 shares were traded on the counter so far as against the average daily volumes of 3711 shares in the past one month.Jyoti CNC Automation Ltd dropped 8.06% to Rs 604. The stock was the fourth biggest loser in 'A' group.On the BSE, 5.14 lakh shares were traded on the counter so far as against the average daily volumes of 70030 shares in the past one month.Bharat Dynamics Ltd fell 7.90% to Rs 1182. The stock was the fifth biggest loser in 'A' group.On the BSE, 5.14 lakh shares were traded on the counter so far as against the average daily volumes of 89799 shares in the past one month.Powered by Capital Market - Live